These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25850750)

  • 1. Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
    Kaufmann P; Okubo K; Bruderer S; Mant T; Yamada T; Dingemanse J; Mukai H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):195-203. PubMed ID: 25850750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects.
    Bruderer S; Hurst N; Kaufmann P; Dingemanse J
    Pharmacology; 2014; 94(3-4):148-56. PubMed ID: 25277144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
    Kaufmann P; Cruz HG; Krause A; Ulč I; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2016 Aug; 82(2):369-79. PubMed ID: 27062188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on: "pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag".
    Srinivas NR
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):371-2. PubMed ID: 26293236
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study.
    Baldoni D; Bruderer S; Muhsen N; Dingemanse J
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):788-98. PubMed ID: 26152132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Authors' reply to Srinivas: "pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag".
    Kaufmann P; Dingemanse J
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):373-4. PubMed ID: 26293237
    [No Abstract]   [Full Text] [Related]  

  • 8. Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist.
    Kaufmann P; Hurst N; Astruc B; Dingemanse J
    Eur J Clin Pharmacol; 2017 Feb; 73(2):151-156. PubMed ID: 27885399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.
    Boehler M; Bruderer S; Ulč I; Dingemanse J
    Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):115-120. PubMed ID: 28639216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.
    Kaufmann P; Niglis S; Bruderer S; Segrestaa J; Äänismaa P; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2015 Oct; 80(4):670-7. PubMed ID: 25851691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
    Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
    Klose H; Chin KM; Ewert R; Gall H; Parambil J; Poch D; Seyfarth HJ; Axelsen LN; Hsu Schmitz SF; Stein C; Preston IR
    Respir Res; 2021 Feb; 22(1):34. PubMed ID: 33536021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
    Bruderer S; Hurst N; Remenova T; Dingemanse J
    Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
    Bruderer S; Petersen-Sylla M; Boehler M; Remeňová T; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2017 Dec; 83(12):2778-2788. PubMed ID: 28715853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects.
    Bruderer S; Okubo K; Mukai H; Mant T; Dingemanse J
    Clin Ther; 2016 May; 38(5):1228-1236.e1. PubMed ID: 27063071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
    Krause A; Machacek M; Lott D; Hurst N; Bruderer S; Dingemanse J
    CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):477-485. PubMed ID: 28556581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selexipag for the treatment of pulmonary arterial hypertension.
    Noel ZR; Kido K; Macaulay TE
    Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist.
    Hoch M; Darpo B; Remenova T; Stoltz R; Zhou M; Kaufmann P; Bruderer S; Dingemanse J
    Drug Des Devel Ther; 2015; 9():175-85. PubMed ID: 25552906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.